$ATNF
180 Life Sciences Corp.

2023 Q4 Form 10-Q Financial Statement

#000121390023085300 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.489M $2.430M
YoY Change -70.54% -28.92%
% of Gross Profit
Research & Development -$36.36K $972.1K
YoY Change -106.21% 66.69%
% of Gross Profit
Depreciation & Amortization $25.68K $30.00K
YoY Change -31.7% 275.94%
% of Gross Profit
Operating Expenses $1.452M $3.538M
YoY Change -74.25% -12.75%
Operating Profit -$3.538M
YoY Change -12.75%
Interest Expense -$4.480K $11.63K
YoY Change -100.46% 58.33%
% of Operating Profit
Other Income/Expense, Net $21.07K -$9.073M
YoY Change -47.95%
Pretax Income -$1.231M -$12.61M
YoY Change -94.57% -41.31%
Income Tax -$4.390K -$2.345M
% Of Pretax Income
Net Earnings -$1.227M -$10.27M
YoY Change -94.36% -52.22%
Net Earnings / Revenue
Basic Earnings Per Share -$1.29
Diluted Earnings Per Share -$1.97 -$1.29
COMMON SHARES
Basic Shares Outstanding 7.475M shares 5.318M shares
Diluted Shares Outstanding 7.952M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.976M $2.700M
YoY Change -71.65% -24.76%
Cash & Equivalents $1.976M $2.663M
Short-Term Investments
Other Short-Term Assets $1.214M $600.0K
YoY Change -9.22% -98.87%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $3.640M $3.371M
YoY Change -59.23% -48.26%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill $0.00
YoY Change
Intangibles $1.620M $1.587M
YoY Change -2.37% 1.43%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.620M $1.587M
YoY Change -84.89% -94.3%
TOTAL ASSETS
Total Short-Term Assets $3.640M $3.371M
Total Long-Term Assets $1.620M $1.587M
Total Assets $5.259M $4.958M
YoY Change -73.23% -85.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.893M $1.713M
YoY Change 5.07% 68.74%
Accrued Expenses $1.870M $2.376M
YoY Change -18.15% 13.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $1.034M $300.0K
YoY Change -20.97% -6.74%
Total Short-Term Liabilities $5.063M $4.807M
YoY Change -10.52% 1.73%
LONG-TERM LIABILITIES
Long-Term Debt $19.94K $0.00
YoY Change -36.07% -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $19.94K $0.00
YoY Change -36.07% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.063M $4.807M
Total Long-Term Liabilities $19.94K $0.00
Total Liabilities $5.387M $5.107M
YoY Change -35.14% -38.17%
SHAREHOLDERS EQUITY
Retained Earnings -$127.3M -$126.1M
YoY Change 18.56% 47.22%
Common Stock $54.00 $674.00
YoY Change -85.6% -82.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$127.7K -$149.3K
YoY Change
Total Liabilities & Shareholders Equity $5.259M $4.958M
YoY Change -73.23% -85.56%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$1.227M -$10.27M
YoY Change -94.36% -52.22%
Depreciation, Depletion And Amortization $25.68K $30.00K
YoY Change -31.7% 275.94%
Cash From Operating Activities -$2.162M -$1.770M
YoY Change -26.12% -50.78%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.468M 2.450M
YoY Change -77.05% -55.35%
NET CHANGE
Cash From Operating Activities -2.162M -1.770M
Cash From Investing Activities
Cash From Financing Activities 1.468M 2.450M
Net Change In Cash -694.3K 680.0K
YoY Change -120.02% -64.05%
FREE CASH FLOW
Cash From Operating Activities -$2.162M -$1.770M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
usd
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38105
dei Entity Registrant Name
EntityRegistrantName
180 LIFE SCIENCES CORP
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
90-1890354
dei Entity Address Address Line1
EntityAddressAddressLine1
3000 El Camino Real Bldg. 4
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
Palo Alto
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94306
dei City Area Code
CityAreaCode
(650)
dei Local Phone Number
LocalPhoneNumber
507-0669
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7475455 shares
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
2662520 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
6970110 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
708377 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1958280 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
3370897 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
8928390 usd
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1587188 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1658858 usd
CY2022Q4 atnf Inprocess Research And Development
InprocessResearchAndDevelopment
9063000 usd
CY2023Q3 us-gaap Assets
Assets
4958085 usd
CY2022Q4 us-gaap Assets
Assets
19650248 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1713164 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1801210 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2375660 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2284516 usd
CY2023Q3 us-gaap Loans Payable Current
LoansPayableCurrent
332885 usd
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
1308516 usd
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
5605 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
75381 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4806844 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5657782 usd
CY2023Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
22216 usd
CY2022Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
31189 usd
CY2023Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
278352 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
2617359 usd
CY2023Q3 us-gaap Liabilities
Liabilities
5107412 usd
CY2022Q4 us-gaap Liabilities
Liabilities
8306330 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6738456 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6738456 shares
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12610785 usd
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3746906 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3746906 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
674 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
375 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
128815362 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
121637611 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2848811 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2885523 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-126116552 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-107408545 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-149327 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11343918 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4958085 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
19650248 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
972113 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
583177 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2339863 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1688474 usd
CY2023Q3 atnf Research And Development Related Parties
ResearchAndDevelopmentRelatedParties
132881 usd
CY2022Q3 atnf Research And Development Related Parties
ResearchAndDevelopmentRelatedParties
53347 usd
atnf Research And Development Related Parties
ResearchAndDevelopmentRelatedParties
481027 usd
atnf Research And Development Related Parties
ResearchAndDevelopmentRelatedParties
158401 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2433193 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3418628 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9204122 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10405933 usd
atnf General And Administrative Related Parties
GeneralAndAdministrativeRelatedParties
5261 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3538187 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
4055152 usd
us-gaap Operating Expenses
OperatingExpenses
12025012 usd
us-gaap Operating Expenses
OperatingExpenses
12258069 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3538187 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4055152 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-12025012 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-12258069 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
11634 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
7348 usd
us-gaap Interest Expense
InterestExpense
34796 usd
us-gaap Interest Expense
InterestExpense
22117 usd
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1536 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1495 usd
CY2022Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
18872850 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
18872850 usd
CY2023Q3 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
-9063000 usd
us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
-9063000 usd
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2036 usd
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1449908 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-69776 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-14167560 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9072598 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-17431826 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9028020 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4725912 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21486978 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21053032 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16983981 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2345025 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2345025 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10265760 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-21486978 usd
us-gaap Net Income Loss
NetIncomeLoss
-18708007 usd
us-gaap Net Income Loss
NetIncomeLoss
-16983981 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
51316 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1871072 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
36712 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4507204 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10214444 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23358050 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18671295 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21491185 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.29
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.97
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.49
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.29
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.97
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.49
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7951954 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1959087 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5658831 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1790176 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7951954 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1959087 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5658831 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1790176 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11343918 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
557421 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4762078 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
663 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
7139924 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2337706 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
117 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
382182 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
551310 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3680169 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-15267 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
6715803 usd
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
60624 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2459282 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
66 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
245348 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
583994 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10265760 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
51316 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-149327 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
39322695 usd
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
149718 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
596467 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
1563713 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-728081 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
40904512 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
60627 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
795052 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
2939284 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-1908051 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
42791424 usd
CY2022Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
60622 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2562265 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
155 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3407490 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
611461 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-21486978 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
-1871072 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
26075367 usd
us-gaap Net Income Loss
NetIncomeLoss
-18708007 usd
us-gaap Net Income Loss
NetIncomeLoss
-16983981 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
60624 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
270967 usd
atnf Amortization Of Stock Options And Restricted Stock Units
AmortizationOfStockOptionsAndRestrictedStockUnits
-1692725 usd
atnf Amortization Of Stock Options And Restricted Stock Units
AmortizationOfStockOptionsAndRestrictedStockUnits
-2002980 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
83015 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
71396 usd
us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
-9063000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
18872850 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-69776 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-14167560 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2345025 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1273033 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-36340 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-99169 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
428632 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
94778 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
127449 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
9945798 usd
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
7783151 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8762209 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9200830 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
985175 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
1491986 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4439526 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4477924 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15093 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87037 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4307590 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4635869 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6970110 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8224508 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2662520 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3588639 usd
us-gaap Interest Paid Net
InterestPaidNet
21722 usd
us-gaap Interest Paid Net
InterestPaidNet
13423 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - BUSINESS ORGANIZATION AND NATURE OF OPERATIONS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">180 Life Sciences Corp., formerly known as KBL Merger Corp. IV (“180LS”, or together with its subsidiaries, the “Company”), was a blank check company organized under the laws of the State of Delaware on September 7, 2016. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. On November 6, 2020, a business combination was consummated following a special meeting of stockholders, where the stockholders of the Company considered and approved, among other matters, a proposal to adopt a Business Combination Agreement. Pursuant to the Business Combination Agreement, KBL Merger Sub, Inc. merged with 180 Life Corp. (f/k/a 180 Life Sciences Corp.) (“<span style="text-decoration:underline">180</span>”), with 180 continuing as the surviving entity and becoming a wholly-owned subsidiary of the Company (the “Business Combination”). References to “KBL” refer to the Company prior to the November 6, 2020 Business Combination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is a clinical stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis and other inflammatory diseases, where anti-TNF therapy will provide a clear benefit to patients, by employing innovative research, and, where appropriate, combination therapy. We have three product development platforms:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fibrosis and anti-tumor necrosis factor (“TNF”);</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">drugs which are derivatives of cannabidiol (“CBD”); and</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">alpha 7 nicotinic acetylcholine receptor (“α7nAChR”).</span></td></tr> </table>
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-126116552 usd
CY2023Q3 atnf Working Capital Deficit
WorkingCapitalDeficit
1435947 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10265760 usd
us-gaap Net Income Loss
NetIncomeLoss
-18708007 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8762209 usd
CY2023Q2 atnf Gross Proceeds For Stock Issued
GrossProceedsForStockIssued
3000000 usd
CY2023Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
667000 shares
CY2023Q3 atnf Gross Proceeds For Stock Issued
GrossProceedsForStockIssued
3000000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the condensed consolidated financial statements. The Company’s significant estimates and assumptions used in these condensed consolidated financial statements include, but are not limited to, the fair value of financial instruments warrants, options and equity shares, as well as the valuation of stock-based compensation and the estimates and assumptions related to impairment analysis of in-process research and development assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and may cause actual results to differ from those estimates.</span></p>
us-gaap Foreign Currency Translation Adjustment Description
ForeignCurrencyTranslationAdjustmentDescription
The functional currency of certain subsidiaries was the British Pound (“GBP”) (1.2386 and 1.2098 GBP to 1 US dollar, each as of September 30, 2023 and December 31, 2022, respectively) for balance sheet accounts, while expense accounts are translated at the weighted average exchange rate for the period (1.2655 and 1.1772 GBP to 1 US dollar for each of the three months ended September 30, 2023 and 2022, respectively, and 1.2442 and 1.2597 GBP to 1 US dollar each for the nine months ended September 30, 2023 and 2022, respectively). Equity accounts are translated at historical exchange rates. The resulting translation adjustments are recognized in stockholders’ (deficit) equity as a component of accumulated other comprehensive (loss) income.
CY2023Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
51316 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-1871072 usd
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
36712 usd
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-4507204 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2952 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1485 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-14031 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-14151 usd
CY2022Q4 us-gaap Other Cash Equivalents At Carrying Value
OtherCashEquivalentsAtCarryingValue
12405084 usd
CY2022 us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
-9063000 usd
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
3342084 usd
CY2022Q4 atnf In Process Research And Development After Impairment
InProcessResearchAndDevelopmentAfterImpairment
9063000 usd
atnf Loss Impairment Amount
LossImpairmentAmount
9063000 usd
CY2023Q3 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2300000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-10265760 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-21486978 usd
us-gaap Net Income Loss
NetIncomeLoss
-18708007 usd
us-gaap Net Income Loss
NetIncomeLoss
-16983981 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7951954 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1959087 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5658831 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1790176 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7951954 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1959087 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5658831 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1790176 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.29
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-10.97
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.49
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.29
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-10.97
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.49
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3284483 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1027257 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3284483 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1027257 shares
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
208064 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1027292 usd
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
51639 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
546563 usd
us-gaap Professional Fees
ProfessionalFees
369906 usd
CY2022 us-gaap Professional Fees
ProfessionalFees
310017 usd
CY2023Q3 us-gaap Value Added Tax Receivable
ValueAddedTaxReceivable
53134 usd
CY2022Q4 us-gaap Value Added Tax Receivable
ValueAddedTaxReceivable
48774 usd
CY2023Q3 us-gaap Prepaid Taxes
PrepaidTaxes
25634 usd
CY2022Q4 us-gaap Prepaid Taxes
PrepaidTaxes
25634 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
708377 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1958280 usd
CY2023Q3 atnf Consulting Fees
ConsultingFees
582476 usd
CY2022Q4 atnf Consulting Fees
ConsultingFees
531829 usd
CY2023Q3 atnf Accrued Expenses Professional Fees
AccruedExpensesProfessionalFees
125000 usd
CY2022Q4 atnf Accrued Expenses Professional Fees
AccruedExpensesProfessionalFees
3945 usd
CY2023Q3 atnf Litigation Accrual
LitigationAccrual
49999 usd
CY2022Q4 atnf Litigation Accrual
LitigationAccrual
125255 usd
CY2023Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1367453 usd
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1558024 usd
CY2023Q3 atnf Research And Development Fees
ResearchAndDevelopmentFees
175165 usd
CY2022Q4 atnf Research And Development Fees
ResearchAndDevelopmentFees
22023 usd
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
66415 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
36422 usd
CY2023Q3 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
9152 usd
CY2022Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
7018 usd
CY2023Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
2375660 usd
CY2022Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
2284516 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
0.0061 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
0.0339 pure
CY2022Q3 us-gaap Increase Decrease In Fair Value Of Price Risk Fair Value Hedging Instruments1
IncreaseDecreaseInFairValueOfPriceRiskFairValueHedgingInstruments1
3762 usd
us-gaap Increase Decrease In Fair Value Of Price Risk Fair Value Hedging Instruments1
IncreaseDecreaseInFairValueOfPriceRiskFairValueHedgingInstruments1
137698 usd
atnf Warrant Purchase Share
WarrantPurchaseShare
1250 shares
CY2023Q3 atnf Exercise Price Per Shares
ExercisePricePerShares
141.4
atnf Outstanding Warrants Percentage
OutstandingWarrantsPercentage
0.10 pure
CY2023Q3 us-gaap Interest Expense Other
InterestExpenseOther
11633 usd
CY2022Q3 us-gaap Interest Expense Other
InterestExpenseOther
7348 usd
CY2023Q3 atnf Interest Expenses Related Parties
InterestExpensesRelatedParties
0 usd
CY2022Q3 atnf Interest Expenses Related Parties
InterestExpensesRelatedParties
1536 usd
us-gaap Interest Expense Other
InterestExpenseOther
34796 usd
us-gaap Interest Expense Other
InterestExpenseOther
22117 usd
atnf Interest Expenses Related Parties
InterestExpensesRelatedParties
0 usd
atnf Interest Expenses Related Parties
InterestExpensesRelatedParties
1495 usd
CY2023Q3 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
0 usd
CY2022Q4 us-gaap Deposit Liabilities Accrued Interest
DepositLiabilitiesAccruedInterest
37960 usd
CY2022Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
16770 usd
CY2021Q3 us-gaap Product Liability Contingency Loss Exposure In Excess Of Accrual Best Estimate
ProductLiabilityContingencyLossExposureInExcessOfAccrualBestEstimate
11286570 usd
CY2022Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
371178 usd
CY2022Q1 atnf Debt Additional Amount
DebtAdditionalAmount
300000 usd
CY2022Q2 us-gaap Payments For Fees
PaymentsForFees
714557 usd
CY2023Q3 us-gaap Interest Receivable
InterestReceivable
6776686 usd
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
4395000 cad
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
3257574 usd
atnf Additional Sum Of Amount
AdditionalSumOfAmount
2721036 usd
CY2022Q3 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
2000000 usd
CY2023Q3 atnf Bid Price Per Share
BidPricePerShare
1
atnf Bid Price Per Share
BidPricePerShare
1
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Stock Issued During Period Shares Purchase Of Assets
StockIssuedDuringPeriodSharesPurchaseOfAssets
400000 shares
CY2023Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1170680 shares
CY2023Q2 atnf Financing Receivable Writeoff After Recovery To Average Outstanding Percentage
FinancingReceivableWriteoffAfterRecoveryToAverageOutstandingPercentage
0.0999 pure
CY2023Q2 atnf Warrant Purchase Price
WarrantPurchasePrice
1.78
CY2023Q2 atnf Warrants Exercisable Years
WarrantsExercisableYears
P5Y6M
CY2023Q2 atnf Prefunded Warrant Exercised
PrefundedWarrantExercised
117 usd
us-gaap Treasury Stock Acquired Purchase Price Significantly In Excess Of Current Market Price
TreasuryStockAcquiredPurchasePriceSignificantlyInExcessOfCurrentMarketPrice
To assess for the change in relative fair value, the Company performed a Black Scholes Option Model calculation to quantify the fair value of the common warrants under their original terms as of the modification date using the following assumptions: a share price of $1.43, exercise prices of $21.20 and $3.50 for the July 2022 common warrants and December 2022 common warrants, respectively, an expected term of 4.8 and 5.2 years, respectively, volatility of 106%, a dividend rate of 0% and a discount rate of 3.36. The Company then performed a Black Scholes Option Model calculation to quantify the fair value of the common warrants with their new modified terms as of the modification date using the following assumptions: a share price of $1.43, an exercise price of $1.78 for both the July 2022 common warrants and December 2022 common warrants, an expected term of 5.5 years, volatility of 106%, a dividend rate of 0% and a discount rate of 3.36. The aggregate difference of approximately $0.8 million between the two calculated amounts was recorded as an equity issuance cost within equity during the period to account for the change in relative fair value.
CY2023Q3 us-gaap Shares Issued
SharesIssued
470000 shares
CY2023Q3 atnf Aggregate Share Of Common Stock
AggregateShareOfCommonStock
666925 shares
CY2023Q3 us-gaap Class Of Warrant Or Right Unissued
ClassOfWarrantOrRightUnissued
3948460 shares
CY2023Q3 atnf Common Stock Warrants To Purchase
CommonStockWarrantsToPurchase
4615385 shares
us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
0.65
CY2023Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
3000000 usd
CY2023Q3 atnf Warrants Purchase Price
WarrantsPurchasePrice
0.0001 shares
CY2023Q3 atnf Financing Receivable Writeoff After Recovery To Average Outstanding Percentage
FinancingReceivableWriteoffAfterRecoveryToAverageOutstandingPercentage
0.0999 pure
CY2023Q3 atnf Warrants Exercisable Years
WarrantsExercisableYears
P5Y
CY2023Q2 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
306604 usd
CY2022Q4 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
2571429 usd
CY2022Q2 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
1570680 usd
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.78
CY2023Q3 us-gaap Share Price
SharePrice
0.84
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
1.78
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y2M4D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
1 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
0.0412 pure
CY2023Q3 atnf Change In Relative Fair Value
ChangeInRelativeFairValue
1400000 usd
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
90485 shares
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
60624 usd
CY2023Q3 us-gaap Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
3645 shares
CY2022Q3 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
6075 usd
us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
20250 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
275 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
190 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
55 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
30 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
81
us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
2430 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P0Y3M
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
162956 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
84.63
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P8Y7M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
269776 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.67
atnf Share Based Compensation Arrangement Weighted Average Remaining Termin Years Granted
ShareBasedCompensationArrangementWeightedAverageRemainingTerminYearsGranted
P9Y10M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
15000 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
417732 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
30.61
atnf Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Option Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionWeightedAverageRemainingContractualTerm2
P9Y2M12D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
177987 shares
CY2023Q3 atnf Weighted Average Exercise Price Exercisable Ending
WeightedAverageExercisePriceExercisableEnding
55.52
atnf Share Based Compensation Weighted Average Remaining Termin Years Exercisable Ending
ShareBasedCompensationWeightedAverageRemainingTerminYearsExercisableEnding
P8Y6M
CY2023Q3 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
60624 usd
us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
583994 usd
us-gaap Restricted Stock Expense
RestrictedStockExpense
1692725 usd
CY2023Q3 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
563361 usd
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
1504768 usd
CY2023Q3 us-gaap Deferred Compensation Arrangement With Individual Compensation Expense
DeferredCompensationArrangementWithIndividualCompensationExpense
672083 usd
us-gaap Deferred Compensation Arrangement With Individual Compensation Expense
DeferredCompensationArrangementWithIndividualCompensationExpense
2273947 usd
CY2023Q3 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
87846 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
314028 usd
atnf Weighted Average Remaining Vesting Period
WeightedAverageRemainingVestingPeriod
P1Y5M23D
CY2023Q3 atnf Research And Development Related Parties
ResearchAndDevelopmentRelatedParties
132881 usd
CY2022Q3 atnf Research And Development Related Parties
ResearchAndDevelopmentRelatedParties
53347 usd
atnf Research And Development Related Parties
ResearchAndDevelopmentRelatedParties
481027 usd
atnf Research And Development Related Parties
ResearchAndDevelopmentRelatedParties
158401 usd
atnf General And Administrative Related Parties
GeneralAndAdministrativeRelatedParties
5261 usd
atnf Stockholder
Stockholder
0.05 pure
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1536 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1495 usd
atnf Stockholder Interest
StockholderInterest
0.05 pure
CY2023Q3 atnf General And Administrative Related Parties
GeneralAndAdministrativeRelatedParties
usd
CY2022Q3 atnf General And Administrative Related Parties
GeneralAndAdministrativeRelatedParties
usd
atnf General And Administrative Related Parties
GeneralAndAdministrativeRelatedParties
usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
usd
CY2023Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
usd
us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
atnf Share Based Compensation Arrangement Weighted Average Remaining Termin Years Exercised
ShareBasedCompensationArrangementWeightedAverageRemainingTerminYearsExercised
atnf Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercised
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised
usd
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
atnf Share Based Compensation Arrangement Weighted Average Remaining Termin Years Expired
ShareBasedCompensationArrangementWeightedAverageRemainingTerminYearsExpired
atnf Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Expired
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpired
usd
CY2023Q3 atnf General And Administrative Related Parties
GeneralAndAdministrativeRelatedParties
usd
CY2022Q3 atnf General And Administrative Related Parties
GeneralAndAdministrativeRelatedParties
usd
atnf General And Administrative Related Parties
GeneralAndAdministrativeRelatedParties
usd
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001690080

Files In Submission

Name View Source Status
atnf-20230930_cal.xml Edgar Link unprocessable
atnf-20230930_lab.xml Edgar Link unprocessable
0001213900-23-085300-index-headers.html Edgar Link pending
0001213900-23-085300-index.html Edgar Link pending
0001213900-23-085300.txt Edgar Link pending
0001213900-23-085300-xbrl.zip Edgar Link pending
atnf-20230930.xsd Edgar Link pending
f10q0923ex10-4_180lifesci.htm Edgar Link pending
f10q0923ex31-1_180lifesci.htm Edgar Link pending
f10q0923ex31-2_180lifesci.htm Edgar Link pending
f10q0923ex32-1_180lifesci.htm Edgar Link pending
f10q0923ex32-2_180lifesci.htm Edgar Link pending
f10q0923_180lifesci.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
atnf-20230930_def.xml Edgar Link unprocessable
atnf-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
f10q0923_180lifesci_htm.xml Edgar Link completed
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending